{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"ADA positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"NAb positive"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Number of participants with ADA and NAb against PF-06863135 were reported in this outcome measure. A participant was ADA (or NAb) positive if: (1) baseline titer was missing or negative and participant had \\>= 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \\>= 4-folder dilution increase in titer from baseline in \\>= 1 post-treatment sample (treatment-boosted).","groups":[{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 44 mcg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 76 mcg as a SC injection Q1W on Day 1, 8, 15 and 22 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG000","title":"Part 2A: PF-06863135 SC"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The immunogenicity analysis set was defined as participants who received at least 1 dose of study treatment and have at least 1 ADA sample collected.","reportingStatus":"POSTED","timeFrame":"From first dose of the study treatment (Day 1) up to end of study treatment (maximum up to 34.3 months)","title":"Part 2: Number of Participants With ADA and NAb Against PF-06863135","type":"SECONDARY","unitOfMeasure":"Participants"}